Current disease status-First occurrence of the cancer - Page 38 of 59 Posts on Medivizor
Navigation Menu

Current disease status-First occurrence of the cancer Posts on Medivizor

Dalotuzumab in extensive-stage small-cell lung cancer

Dalotuzumab in extensive-stage small-cell lung cancer

Posted by on Mar 30, 2015 in Lung cancer | 0 comments

In a nutshell The authors aimed to determine the effects of dalotuzumab in treating small-cell lung cancer when combined with cisplatin and etoposide. Some background Extensive-stage small-cell lung cancer (SCLC – cancer has spread outside of the chest) represents 15% of all lung cancer cases. Though numerous treatments have been used over...

Read More

High YAP protein levels indicate improved treatment response in lung cancer patients

High YAP protein levels indicate improved treatment response in lung cancer patients

Posted by on Mar 16, 2015 in Lung cancer | 0 comments

In a nutshell The authors aimed to determine whether levels of YAP protein could predict the success of treatment in patients with lung cancer. Some background YAP protein is a protein active in many cancers that can have a positive or negative effect depending on the location. When YAP protein is present in the nucleus (brain of the cancer...

Read More

Hormone therapy before radiation therapy: reduced survival in low-risk prostate cancer?

Hormone therapy before radiation therapy: reduced survival in low-risk prostate cancer?

Posted by on Mar 13, 2015 in Prostate cancer | 0 comments

In a nutshell This study investigated the effects of hormone therapy given before brachytherapy (a form of radiation therapy) on the survival of prostate cancer patients with at least one risk factor for coronary artery disease compared to those with no risk factors.  Some background Quite often, hormone therapy such as anti-androgen therapy...

Read More

BNP hormone can be used to determine the risk of post-surgery complications in lung cancer

BNP hormone can be used to determine the risk of post-surgery complications in lung cancer

Posted by on Mar 9, 2015 in Lung cancer | 0 comments

In a nutshell The authors aimed to determine whether a specific hormone could predict patients who would experience complications after lung cancer surgery.  Some background B-type natriuretic peptide (BNP) is a hormone produced by the heart when it is under pressure or over-worked and is commonly used to determine the risk of heart failure....

Read More

What is recommended for patients with HER2 positive cancer that has spread to the brain?

What is recommended for patients with HER2 positive cancer that has spread to the brain?

Posted by on Mar 9, 2015 in Breast cancer | 0 comments

In a nutshell This paper gave recommendations for treating patients with human epidermal growth factor receptor 2- positive (presence of HER2 on cancer cells) breast cancer that has spread to the brain.   Some background Some patients have breast cancer where human epidermal growth factor receptor 2 (HER2, a protein) is present. With...

Read More

Tafinlar vs DTIC in metastatic melanoma; which has better quality-of-life outcomes?

Posted by on Feb 23, 2015 in Melanoma | 0 comments

In a nutshell The authors aimed to determine the quality-of-life benefits for metastatic melanoma patients treated with dabrafenib compared to dacarbazine. Some background Metastatic melanoma is melanoma that has spread out to other parts of the body from the primary tumor site. Dabrafenib (Tafinlar) and dacarbazine (DTIC) are drugs used to treat...

Read More

Combo of taxane + bevacizumab + capecitabine is not recommended in metastatic breast cancer

Posted by on Feb 16, 2015 in Breast cancer | 0 comments

In a nutshell The authors studied the efficacy of taxanes (class of drugs including paclitaxel [Taxol] and docetaxel [Taxotere]) plus bevacizumab (Avastin) with or without capecitabine (Xeloda) in treating metastatic breast cancer.  Some background Bevacizumab has been studied for the treatment of breast cancer that is metastatic (that...

Read More

Anastomotic leakage in rectal cancer patients: a major surgical complication but not a major long-term risk factor

Anastomotic leakage in rectal cancer patients: a major surgical complication but not a major long-term risk factor

Posted by on Feb 9, 2015 in Colorectal cancer | 0 comments

In a nutshell This study investigated the impact of anastomotic leakage, a major surgical complication, on the risk for rectal cancer returning. Some background The main treatment option for patients with rectal cancer is surgery. One major complication that can occur after surgery is anastomotic leakage. Generally this involves the leakage of...

Read More